2012 ASCO Annual Meeting Saturday

Chicago, IL - ASCO 2012 Annual Meeting: - Johann S. De Bono, MB, ChB, FRCP, MSc, PhD Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. during New Paradigms for Hormone Therapy in Prostate Cancer at the American Society for Clinical Oncology (ASCO) Annual Meeting here today, Saturday June 2, 2012. Over 31,000 physicians, researchers and healthcare professionals from over 100 countries are attending the meeting which is being held at the McCormick Convention center and features the latest cancer research in the areas of basic and clinical science. Photo by © ASCO/Silas Crews 2012 Technical Questions: todd@toddbuchanan.com; ASCO Contact: photos@asco.org